CNS Pharmaceuticals (CNSP) Payables (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Payables came in at $4.1 million in Q4 2025, up 62.46% YoY from $2.5 million in Q4 2024, and up 109.32% on a QoQ basis from $2.0 million in Q3 2025.
CNS Pharmaceuticals (CNSP) Payables (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of Payables data on file, last reported at $4.1 million in Q4 2025.
- Quarterly Payables rose 62.46% year-over-year to $4.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.1 million (up 62.46% YoY) and the FY2025 annual result came in at $4.1 million, up 62.46% from the prior year.
- Payables grew to $4.1 million in Q4 2025, from $2.0 million in the prior quarter.
- In the past five years, Payables ranged from a high of $6.8 million in Q2 2024 to a low of $865321.0 in Q3 2022.
- A 5-year average of $3.1 million and a median of $2.7 million in 2024 frame the typical range for Payables.
- Annual changes were most pronounced in 2021 — Payables soared 614.69% — and 2025, when it plunged 79.55%.
- Tracing CNSP's Payables over 5 years: stood at $2.4 million in 2021, then jumped by 107.67% to $4.9 million in 2022, then increased by 24.65% to $6.1 million in 2023, then slumped by 58.84% to $2.5 million in 2024, then jumped by 62.46% to $4.1 million in 2025.
- The last three Payables figures came in at $4.1 million (Q4 2025), $2.0 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | CNS Pharmaceuticals | 2.66 Mn | -4.54 Mn | - | 4.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.10 Mn |
| Sep 30, 2025 | 1.96 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Mar 31, 2025 | 2.78 Mn |
| Dec 31, 2024 | 2.52 Mn |
| Sep 30, 2024 | 4.06 Mn |
| Jun 30, 2024 | 6.76 Mn |
| Mar 31, 2024 | 6.09 Mn |
| Dec 31, 2023 | 6.13 Mn |
| Sep 30, 2023 | 4.07 Mn |
| Jun 30, 2023 | 3.74 Mn |
| Mar 31, 2023 | 3.07 Mn |
| Dec 31, 2022 | 4.92 Mn |
| Sep 30, 2022 | 865,321.00 |
| Jun 30, 2022 | 1.47 Mn |
| Mar 31, 2022 | 1.10 Mn |
| Dec 31, 2021 | 2.37 Mn |
| Sep 30, 2021 | 1.51 Mn |
| Jun 30, 2021 | 1.07 Mn |
| Mar 31, 2021 | 1.37 Mn |